Since 2005, there has been a shift to focus on patient-reported and patient-centric initiatives in support of drug development planning and execution by health authorities. In oncology, the practice of patient-centric care is particularly important, as there are challenging trade-offs to be made between the benefit and risks of drugs throughout different stages of disease progression. One treatment could benefit a particular outcome such as survival, but negatively influence another, like patient independence¹, therefore treatment choice will be influenced by the patient’s preference for outcomes.

Join IQVIA's panel of experts as we address the following topics:

• Understanding supplementary evidence needs to support market access and launch:
  • The role of evidence generated from patient preference studies in oncology
  • Best practices and strategies for patient-centric evidence generation
• How patient preference research allows us to generate scientifically robust data:
  • Key preference methodologies to generate patient preference data for treatment characteristics and outcomes, and considerations for selection
  • Example cases demonstrating the impact of patient preference evidence
• Regulatory authority perspectives of preference methodologies:
  • FDA and EMA’s perspective for the use of preference information
  • HTA bodies and payers’ perspectives for the use of preference information
  • Preferences to support the clinicians’ and the patients’ perspectives
• The future for preference research in oncology

1: Seghers PAL, Wiersma A, Festen S, Stegmann ME, Soubeyran P, Rostoft S, O’Hanlon S, Portielje JEA, Hamaker ME. Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review. Cancers. 2022; 14(5):1147. https://doi.org/10.3390/cancers14051147